LBA57 Unicancer PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC)

T. Conroy; P. Hammel; A. Turpin; C. Belletier; A. Wei; E. Mitry; A. Lopez; E. Francois; P. Artru; J. Biagi; T. Lecomte; E. Assenat; R. Faroux; M. Ychou; O. Bouche; A. Lambert; L. Monard; P. Rat; F. Castan; J-B. Bachet

doi:10.1016/j.annonc.2021.08.2137

Retour

LBA57 Unicancer PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC)

Article de revue

Avec comité de lecture

LBA57 Unicancer PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC)

T. Conroy, P. Hammel, A. Turpin, C. Belletier, A. Wei, E. Mitry, A. Lopez, E. Francois, P. Artru, J. Biagi, …

Annals of oncology, Vol.32, pp.S1334-S1334

09/2021

DOI: https://doi.org/10.1016/j.annonc.2021.08.2137

Indicateurs

1 Consultations de la notice

Détails

Titre: LBA57 Unicancer PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC)
Créateurs - sans rôle: T. Conroy - Institut de Cancérologie de Lorraine
P. Hammel - Digestive Oncology Department, Hopital Beaujon, Clichy, France
A. Turpin - Digestive Oncology Department, C.H.U. Claude Huriez, Lille, France
C. Belletier - Medical Oncology Department, Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg, France
A. Wei - General Surgery, University Health Network - Princess Margaret Cancer Center, Toronto, ON, Canada
E. Mitry - Institut Paoli-Calmettes
A. Lopez - Gastroenterology and Hepatology, CHU Nancy-Brabois Hospital, Vandoeuvre Les Nancy, France
E. Francois - Oncology Department, Centre Anticancer Antoine Lacassagne, Nice, France
P. Artru - GI Oncology Department, Hôpital privé Jean Mermoz, Lyon, France
J. Biagi - Oncology Department, Cancer Centre of Southeastern Ontario, Kingston, ON, Canada
T. Lecomte - Gastroenterology and Hepatology, CHU de Tours, Hôpital Trousseau, Chambray-lès-Tours, France
E. Assenat - Medical Oncology, CHU Saint-Eloi, Montpellier, France
R. Faroux - Gastroenterology and Hepatology, CHD Vendee, La Roche Sur Yon, France
M. Ychou - Digestive Oncology Department, ICM Regional Cancer Institute of Montpellier, Montpellier, France
O. Bouche - Hôpital Robert-Debré
A. Lambert - Medical Oncology Department, Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre-lès-Nancy, France
L. Monard - UCGI, UNICANCER, Paris, France
P. Rat - Digestive surgery, CHU Dijon, Le Bocage hospital, Dijon, France
F. Castan - Biometry Department, ICM Regional Cancer Institute of Montpellier, Montpellier, France
J-B. Bachet - Gastroenterology and Hepatology, Groupe Hospitalier Pitié Salpetriere, Paris, France
Détails de publication: Annals of oncology, Vol.32, pp.S1334-S1334
Éditeur: Elsevier Ltd
Identifiants: 99140060709311
Unité académique: Institut de Recherche en Cancérologie de Montpellier - IRCM
Langue: English
Type de ressource: Journal article